Management of Stage IIIA HER2-Positive Breast Cancer After Neoadjuvant Therapy

Adjuvant Therapy

The American Society of Clinical Oncology recommends adjuvant endocrine therapy with either tamoxifen or an aromatase inhibitor for hormone receptor-positive disease, with tamoxifen being the appropriate choice for premenopausal patients 1
For patients with ER+/PR+ status and premenopausal status, tamoxifen 20 mg daily for 5 years is the recommended endocrine therapy 1

The NCCN panel recommends up to 1 year of HER2-targeted therapy with trastuzumab based on multiple randomized trials demonstrating clinically significant improvements in disease-free survival and overall survival 3
If residual invasive disease is present after neoadjuvant therapy, consider switching to trastuzumab emtansine (T-DM1) instead of continuing trastuzumab, based on the KATHERINE trial showing superior outcomes with T-DM1 in patients with residual disease 1, 2

Radiation therapy indications must be based on pre-chemotherapy tumor characteristics, not post-neoadjuvant pathology, with post-mastectomy radiotherapy to the chest wall and regional lymph nodes recommended for patients with initial Stage IIIA disease (cT3N1M0) 1, 2

Evaluate left ventricular ejection fraction (LVEF) prior to continuing trastuzumab and every 3 months during therapy, due to increased cardiac toxicity observed with trastuzumab, particularly when combined with anthracyclines 3

Annual mammography of the contralateral breast is recommended, but routine imaging (CT, PET, bone scans) is not indicated in asymptomatic patients, with surveillance focusing on clinical examination and contralateral breast screening 1
Initial follow-up should occur 7-14 days post-operatively to assess wound healing, drain output, and review final pathology results, which will determine whether to continue trastuzumab or switch to T-DM1 based on residual disease status 1, 2